Red yeast rice, LDL cholesterol, dietary supplements, statins, European regulation
For years, monacolin K has symbolized the meeting point between nutraceuticals and cholesterol management. Authorized with an official claim by EFSA, it has become firmly established in the dietary supplement market aimed at maintaining normal LDL cholesterol levels.
Today, however, the scenario has changed. The new scientific opinion of the European Authority has raised serious concerns about the safety of this substance, opening a regulatory debate that could have significant consequences for the entire sector.
From Claim Authorization to the Safety Debate
In 2011, EFSA recognized a cause-and-effect relationship between the daily intake of 10 mg of monacolin K from red yeast rice and the maintenance of normal blood cholesterol levels, pursuant to Regulation (EC) No. 1924/2006.
With the subsequent Regulation (EU) No. 432/2012, the health claim was authorized, provided that the beneficial effect was achieved with a daily intake of 10 mg of monacolin K.
In Italy, this decision led to an increase in the maximum permitted daily dose in supplements, encouraging the widespread use of red yeast rice in the nutraceutical market.
The Central Issue: Identity with Lovastatin
The turning point of the new opinion concerns the very nature of monacolin K. The Scientific Panel clarified that monacolin K in its lactone form is chemically identical to lovastatin, the active substance in medicinal products used to treat hypercholesterolemia.
Both substances act by inhibiting the enzyme HMG-CoA reductase, which is involved in cholesterol synthesis. This means that the biological effect of the supplement is not merely “nutritional,” but overlaps with that of a pharmaceutical product belonging to the statin class.
It is precisely this overlap that raises significant safety concerns.
Adverse Effects and Pharmacovigilance Reports
Information collected from various international sources indicates that the adverse effects associated with red yeast rice involve the same organs and systems affected during treatment with lovastatin. The most frequently reported reactions concern the musculoskeletal system, including cases of rhabdomyolysis, but hepatic alterations, neurological disorders, and gastrointestinal issues have also been reported.
A particularly critical element is that some serious adverse reactions have been observed even at dosages lower than 10 mg per day, in some cases starting at 3 mg. This makes it difficult to identify a reliable safety threshold.
Scientific Uncertainties Highlighted by EFSA
The opinion highlights several areas of uncertainty. The composition of red yeast rice supplements is not uniform, and the monacolin content may vary significantly from one product to another. The ratio between the lactone and acid forms of monacolin K is also inconsistent, with possible differences in bioavailability.
In addition, many products on the market are multi-component formulations in which monacolin K is combined with other botanical or nutritional substances. Potential interactions, as well as concomitant use with drugs or foods that affect hepatic metabolism, represent further elements of uncertainty.
The Panel’s Conclusion: No Risk-Free Dose Identified
The conclusion of EFSA is clear and carries significant regulatory weight: it was not possible to identify a level of intake of monacolins from red yeast rice that does not raise concerns for the health of the general population and vulnerable groups.
In the absence of a dose considered safe, the issue now moves to the European Commission, which may intervene pursuant to Article 8 of Regulation (EC) No. 1925/2006. The options range from a total ban to the introduction of specific restrictions or placement on a monitoring list.
What Are the Scenarios for the Supplement Market?
The nutraceutical sector now faces a delicate phase. The possible application of the precautionary principle could significantly modify the regulatory framework for red yeast rice in Europe, with impacts on formulations, positioning strategies, and claim management.
The decision-making process will involve Member States and the relevant working groups, but it is clear that monacolin K can no longer be considered an ingredient free from regulatory concerns.
The issue does not concern just a single ingredient, but the increasingly thin boundary between supplement and medicine.
Source: EFSA Journal, Scientific Opinion on the safety of monacolins in red yeast rice, adopted on 28 July 2018 and published on 3 August 2018.
